Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease

Clarisse Roux-Marson, Jean Baptiste Baranski, Coraline Fafin, Guillaume Exterman, Cecile Vigneau, Cecile Couchoud, Olivier Moranne, P S P A Investigators, Clarisse Roux-Marson, Jean Baptiste Baranski, Coraline Fafin, Guillaume Exterman, Cecile Vigneau, Cecile Couchoud, Olivier Moranne, P S P A Investigators

Abstract

Background: Elderly patients with chronic kidney disease (CKD) frequently present comorbidities that put them at risk of polypharmacy and medication-related problems. This study aims to describe the overall medication profile of patients aged ≥75 years with advanced CKD from a multicenter French study and specifically the renally (RIMs) and potentially inappropriate-for-the-elderly medications (PIMs) that they take.

Methods: This is a cross-sectional analysis of medication profiles of individuals aged ≥75 years with eGFR < 20 ml/min/1.73 m2 followed by a nephrologist, who collected their active prescriptions at the study inclusion visit. Medication profiles were first analyzed according to route of administration, therapeutic classification. Second, patients were classified according to their risk of potential medication-related problems, based on whether the prescription was a RIM or a PIM. RIMs and PIMs have been defined according to renal appropriateness guidelines and to Beer's criteria in the elderly. RIMs were subclassified by 4 types of category: (a) contraindication; (b) dose modification is recommended based on creatinine clearance (CrCl); (c) dose modification based on CrCl is not recommended but a maximum daily dose is mentioned, (d) no specific recommendations based on CrCl: "use with caution", "avoid in severe impairment", "careful monitoring of dose is required" "reduce the dose".

Results: We collected 5196 individual medication prescriptions for 556 patients, for a median of 9 daily medications [7-11]. Antihypertensive agents, antithrombotics, and antianemics were the classes most frequently prescribed. Moreover, 77.0% of patients had at least 1 medication classified as a RIM. They accounted 31.3% of the drugs prescribed and 9.25% was contraindicated drugs. At least 1 PIM was taken by 57.6 and 45.5% of patients had at least one medication classified as RIM and PIM. The prescriptions most frequently requiring reassessment due to potential adverse effects were for proton pump inhibitors and allopurinol. The PIMs for which deprescription is especially important in this population are rilmenidine, long-term benzodiazepines, and anticholinergic drugs such as hydroxyzine.

Conclusion: We showed potential drug-related problems in elderly patients with advanced CKD. Healthcare providers must reassess each medication prescribed for this population, particularly the specific medications identified here.

Trial registration: NCT02910908.

Keywords: Chronic kidney disease; Elderly; Medication prescription; Polypharmacy.

Conflict of interest statement

Authors have no competing interest to report as described by BMC Geriatrics.

Figures

Fig. 1
Fig. 1
Use of medications classified as renally inappropriate medications (RIMs) and potentially inappropriate-for-the-elderly medications (PIMs)
Fig. 2
Fig. 2
Most frequently medications prescribed at an inappropriate dose for patients with severe chronic kidney disease

References

    1. Breton G, Froissart M, Janus N, Launay-Vacher V, Berr C, Tzourio C, et al. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based study. Nephrol Dial Transplant. 2011;26(9):2852–2859. doi: 10.1093/ndt/gfq827.
    1. Cardone KE, Bacchus S, Assimon MM, Pai AB, Manley HJ. Medication-related problems in CKD. Adv Chronic Kidney Dis. 2010;17(5):404–412. doi: 10.1053/j.ackd.2010.06.004.
    1. Qato D, Caleb G, Johnson M, Schumm P, Tessler LS. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867. doi: 10.1001/jama.2008.892.
    1. Hsu KL, Fink JC, Ginsberg JS, Yoffe M, Zhan M, Fink W, et al. Self-reported medication adherence and adverse patient safety events in CKD. Am J Kidney Dis. 2015;66(4):621–629. doi: 10.1053/j.ajkd.2015.03.026.
    1. Wong NA, Jones HW. An analysis of discharge drug prescribing amongst elderly patients with renal impairment. Postgrad Med J. 1998;74(873):420–422. doi: 10.1136/pgmj.74.873.420.
    1. Chang F, O’Hare AM, Miao Y, Steinman MA. Use of Renally inappropriate medications in older veterans: a National Study. J Am Geriatr Soc. 2015;63(11):2290–2297. doi: 10.1111/jgs.13790.
    1. Bongue B, Laroche ML, Gutton S, Colvez A, Guéguen R, Moulin JJ, et al. Potentially inappropriate drug prescription in the elderly in France: a population-based study from the French National Insurance Healthcare system. Eur J Clin Pharmacol. 2011;67(12):1291–1299. doi: 10.1007/s00228-011-1077-5.
    1. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227–2246. doi: 10.1111/jgs.13702.
    1. Laroche M, Charmes J, Nouaille Y, Fourrier A, Merle L. Impact of hospitalisation in an acute medical geriatric unit on potentially inappropriate medication use. Drugs Aging. 2006;23(1):49–59. doi: 10.2165/00002512-200623010-00005.
    1. Jones SA, Bhandari S. The prevalence of potentially inappropriate medication prescribing in elderly patients with chronic kidney disease. Postgrad Med J. 2013;89(1051):247–250. doi: 10.1136/postgradmedj-2012-130889.
    1. Fick DM, Waller JL, Maclean JR. Potentially inappropriate medication use in a Medicare managed care population: association with higher costs and utilization. J Manag Care Pharm. 2001;7(5):407–413.
    1. Quintana-Bárcena P, Lord A, Lizotte A, Berbiche D, Lalonde L. Prevalence and management of drug-related problems in chronic kidney disease patients by severity level: a subanalysis of a cluster randomized controlled trial in community pharmacies. J Manag Care Spec Pharm. 2018;24(2):173–181.
    1. Moranne O, Couchoud C, Vigneau C. PSPA study investigators. Characteristics and treatment course of patients older than 75 years, reaching end-stage renal failure in France. The PSPA study. J Gerontol A Biol Sci Med Sci. 2012;67(12):1394–1399. doi: 10.1093/gerona/gls162.
    1. WHO Collaborating Centre for Drug Statistics Methodology, ATC/ DDD Index 2009. . Accessed 20 Feb 2020.
    1. Information Conseil Adaptation Rénale ICAR. . Accessed 20 Feb 2020.
    1. EMA. Guideline on the evaluation of the pharmacokinetics of 4 medicinal products in patients with decreased renal 5 function. Available at hhttp://. Accessed 20 Feb 2020.
    1. FDA. Pharmacokinetics in patients with impaired renal function –study design, data analysis, and impact on dosing and labeling. Available at . Accessed 20 Feb 2020.
    1. Laroche M-L, Bouthier F, Merle L, Charmes J-P. Potentially inappropriate medications in the elderly: interest of a list adapted to the French medical practice. Rev Med Interne. 2009;30(7):592–601. doi: 10.1016/j.revmed.2008.08.010.
    1. Gargiulo R, Suhail F, Lerma EV. Cardiovascular disease and chronic kidney disease. Dis Mon. 2015;61(9):403–413. doi: 10.1016/j.disamonth.2015.07.005.
    1. Laroche M-L, Charmes J-P, Nouaille Y, Picard N, Merle L. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol. 2007;63(2):177–186. doi: 10.1111/j.1365-2125.2006.02831.x.
    1. Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M, et al. 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925–1938. doi: 10.1097/HJH.0b013e328364ca4c.
    1. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol. 2001;12(8):1713–1720.
    1. Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, et al. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dial Transplant. 2005;20(6):1110–1115. doi: 10.1093/ndt/gfh771.
    1. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37(3):484–489. doi: 10.1053/ajkd.2001.22070.
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the spec. Eur J Heart Fail. 2016;18(8):891–975. doi: 10.1002/ejhf.592.
    1. Ruilope LM. Chronic kidney disease: blood pressure control in CKD--still a matter of debate. Nat Rev Nephrol. 2013;9(10):572–573. doi: 10.1038/nrneph.2013.180.
    1. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010;25(12):3977–3982. doi: 10.1093/ndt/gfp511.
    1. Moranne O, Froissart M, Rossert J, Gauci C, Boffa J-J, Haymann JP, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol. 2009;20(1):164–171. doi: 10.1681/ASN.2008020159.
    1. Ito T, Jensen RT. Association of Long-Term Proton Pump Inhibitor Therapy with bone fractures and effects on absorption of calcium, vitamin B12, Iron, and magnesium. Curr Gastroenterol Rep. 2010;12(6):448–457. doi: 10.1007/s11894-010-0141-0.
    1. Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, et al. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care. 2012;35(7):1591–1597. doi: 10.2337/dc12-0226.
    1. Aparicio M, Dratwa M, El Esper N, Fillastre JP, Levaltier B, Lins R, et al. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients. Am J Cardiol. 1994;74:43–50. doi: 10.1016/0002-9149(94)90041-8.
    1. Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atheroscler. 2001;90(supp2):174.
    1. Fellström B, Holdaas H, Jardine AG, Rose H, Schmieder R, Wilpshaar W, et al. Effect of Rosuvastatin on outcomes in chronic Haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res. 2007;30(5):314–322. doi: 10.1159/000106803.
    1. Tzeng TB, Schneck DW, Birmingham BK, Mitchell PD, Zhang H, Martin PD, et al. Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin. 2008;24(9):2575–2585. doi: 10.1185/03007990802312807.
    1. Marbury TC, Blum RA, Rauch C, Pinquier J-L. Pharmacokinetics and safety of a single Oral dose of once-daily Alfuzosin, 10 mg, in male subjects with mild to severe renal impairment. J Clin Pharmacol. 2002;42(12):1311–1317. doi: 10.1177/0091270002239360.
    1. Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3–5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European renal best practice (ERBP)*. Nephrol Dial Transplant. 2012;27(10):3736–3745. doi: 10.1093/ndt/gfs295.
    1. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015; 16(1). Available from: 10.1186/s12882-015-0047-z. Cited 2017 Jan 26.
    1. Tesfaye WH, Castelino RL, Wimmer BC, Zaidi STR. Inappropriate prescribing in chronic kidney disease: a systematic review of prevalence, associated clinical outcomes and impact of interventions. Int J Clin Pract. 2017;71(7):e12960. doi: 10.1111/ijcp.12960.
    1. Tawadrous D, Shariff S, Haynes R, Lansavichus A, Jain A, Garg A. Use of clinical decision support Systems for Kidney-Related Drug Prescribing: a systematic review. Am J Kidney Dis. 2011;6(58):903–914. doi: 10.1053/j.ajkd.2011.07.022.
    1. Khanal A, Castelino RL, Peterson GM, Jose MD. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources?: consistency in renal drug dosing guidelines. Intern Med J. 2014;44(1):77–85. doi: 10.1111/imj.12291.
    1. Saheb Sharif-Askari F, Syed Sulaiman SA, Saheb Sharif-Askari N, Al Sayed Hussain A. Development of an Adverse Drug Reaction Risk Assessment Score among Hospitalized Patients with Chronic Kidney Disease. PLoS One. 2014;9(4):e95991. doi: 10.1371/journal.pone.0095991.
    1. Gallagher PF, Barry PJ, Ryan C, Hartigan I, O’Mahony D. Inappropriate prescribing in an acutely ill population of elderly patients as determined by beers’ criteria. Age Ageing. 2007;37(1):96–101. doi: 10.1093/ageing/afm116.
    1. Ruiz-Hurtado G, Sarafidis P, Fernández-Alfonso MS, Waeber B, Ruilope LM. Global cardiovascular protection in chronic kidney disease. Nat Rev Cardiol. 2016;13(10):603–608. doi: 10.1038/nrcardio.2016.48.
    1. Simonsen E, Komenda P, Lerner B, Askin N, Bohm C, Shaw J, et al. Treatment of uremic pruritus: a systematic review. Am J Kidney Dis. 2017;70(5):638–655. doi: 10.1053/j.ajkd.2017.05.018.
    1. De Rhodes KH. The dangers of ignoring the beers criteria-the prescribing Cascade. JAMA Intern Med. 2019;179(7):863–864. doi: 10.1001/jamainternmed.2019.1288.
    1. Weir MR, Fink JC. Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens. 2014;23(3):306–313. doi: 10.1097/01.mnh.0000444912.40418.45.
    1. Vidal dictionaries. 91th ed. Vidal Editions Paris: Vidal SA; 2015.
    1. Leguelinel-Blache G, Dubois F, Bouvet S, Roux-Marson C, Arnaud F, Castelli C, et al. Improving Patientʼs primary medication adherence: the value of pharmaceutical counseling. Medicine (Baltimore) 2015;94(41):e1805. doi: 10.1097/MD.0000000000001805.
    1. McIntyre C, McQuillan R, Bell C, Battistella M. Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy. Am J Kidney Dis. 2017;S0272–6386(17):30582–30586.
    1. Triantafylidis LK, Hawley CE, Perry LP, Paik JM. The role of Deprescribing in older adults with chronic kidney disease. Drugs Aging. 2018;35(11):973–984. doi: 10.1007/s40266-018-0593-8.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit